文献速递心律失常

衰弱老年房颤患者从维生素K拮抗剂转换为NOAC的安全性:FRAIL-AF随机对照试验

Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
PubMed 文献 · Circulation · 2023-08-27

FRAIL-AF试验纳入≥75岁且衰弱评分≥3的房颤患者1330例,随机分为从VKA转换为NOAC组或继续VKA组,随访12个月。因主要出血终点事件达163例而提前终止,转换组主要出血风险显著高于继续组(HR 1.69,95%CI 1.23-2.32),血栓栓塞事件无显著减少(HR 1.26,95%CI 0.60-2.61)。

要点

  • 衰弱老年房颤患者从VKA转换为NOAC增加出血风险。
  • 转换NOAC未减少血栓栓塞事件。
  • 该人群继续VKA治疗可能更安全。

核心结论

  • 在衰弱老年房颤患者中,将INR指导的VKA治疗转换为NOAC与更多出血并发症相关,且未减少血栓栓塞并发症。

研究设计与样本

  • 务实、多中心、开放标签、随机对照优效性试验,纳入≥75岁且Groningen衰弱指数评分≥3的房颤患者,随机分为转换为NOAC组或继续VKA组,随访12个月,采用意向性分析。

主要发现

  • 共1330例患者随机分配(平均年龄83岁,中位衰弱评分4),主要终点事件163例后因无效提前终止。
  • 主要终点(大出血或临床相关非大出血)风险比1.69(95%CI 1.23-2.32),转换组高于继续组。
  • 血栓栓塞事件风险比1.26(95%CI 0.60-2.61)。

临床怎么用

  • 对于正在使用VKA的衰弱老年房颤患者,不应常规转换为NOAC。

局限性

  • 开放标签设计可能引入偏倚;试验因无效提前终止;排除GFR<30 mL·min-1·1.73 m-2及瓣膜性房颤患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is ambiguity whether frail patients with atrial fibrillation managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC). METHODS: We conducted a pragmatic, multicenter, open-label, randomized controlled superiority trial. Older patients with atrial fibrillation living with frailty (≥75 years of age plus a Groningen Frailty Indicator score ≥3) were randomly assigned to switch from international normalized ratio-guided VKA treatment to an NOAC or to continued VKA treatment. Patients with a glomerular filtration rate <30 mL·min-1·1.73 m-2 or with valvular atrial fibrillation were excluded. Follow-up was 12 months. The cause-specific hazard ratio was calculated for occurrence of the primary outcome that was a major or clinically relevant nonmajor bleeding complication, whichever came first, accounting for death as a competing risk. Analyses followed the intention-to-treat principle. Secondary outcomes included thromboembolic events. RESULTS: Between January 2018 and June 2022, a total of 2621 patients were screened for eligibility and 1330 patients were randomly assigned (mean age 83 years, median Groningen Frailty Indicator score 4). After randomization, 6 patients in the switch-to-NOAC arm and 1 patient in the continue-with-VKA arm were excluded due to the presence of exclusion criteria, leaving 662 patients switched from a VKA to an NOAC and 661 patients continued VKAs in the intention-to-treat population. After 163 primary outcome events (101 in the switch arm, 62 in the continue arm), the trial was stopped for futility according to a prespecified futility analysis. The hazard ratio for our primary outcome was 1.69 (95% CI, 1.23-2.32). The hazard ratio for thromboembolic events was 1.26 (95% CI, 0.60-2.61). CONCLUSIONS: Switching international normalized ratio-guided VKA treatment to an NOAC in frail older patients with atrial fibrillation was associated with more bleeding complications compared with continuing VKA treatment, without an associated reduction in thromboembolic complications. REGISTRATION: URL: https://eudract.ema.europa.eu; Unique identifier: 2017-000393-11. URL: https://eudract.ema.europa.eu; Unique identifier: 6721 (FRAIL-AF study).

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Joosten LPT, van Doorn S, van de Ven PM, et al. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2023. PMID: 37634130. doi:10.1161/CIRCULATIONAHA.123.066485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。